Endocyte Secures DOXIL(R) Supply to Support Ongoing Phase 3 PROCEED Trial in Ovarian Cancer .
WEST LAFAYETTE, Ind., Aug 2, 2012 (GlobeNewswire via COMTEX) -- Endocyte, Inc., /quotes/zigman/119422/quotes/nls/ecyt ECYT +3.55% , a biopharmaceutical company developingr .
targeted small molecule drug conjugates (SMDCs) and companion imaging diagnostics for personalized therapy, today announced that the company has secured DOXIL(R) (doxorubicin HCl liposome injection) supply from Janssen Products, LP, to supplement existing supply already in place to support the ongoing Phase 3 PROCEED trial in ovarian cancer. The PROCEED trial compares vintafolide in combination with DOXIL versus DOXIL alone for the treatment of folate-receptor positive platinum resistant ovarian cancer.
"The supply of DOXIL announced today adds to our flexibility in meeting the ongoing needs of the PROCEED trial so we may continue to enroll patients without interruption," said Ron Ellis, president and CEO at Endocyte. "We will continue to work closely with Janssen to ensure that DOXIL supply allows the PROCEED trial to remain on schedule. Current estimates call for new supply of DOXIL to be available by the end of the year."
...
PharmaMar Recibe el Ok de la FDA Para Iniciar Fase I con PM54 en Combi con Inmuno Para Posible Tratamiento . PARA EI RELEVO DE LURBINECTEDIN ESTABAN PM184 Y PM14 AMBOS RETIRADOS POR LA CIA. AHORA HAY OTROS DOS FÁRMACOS EN FASE I EN EL INTENTO DE RELEVAR A LURBINECTEDIN : PM54 Y PM534 ... EL PROBLEMA ES QUE AMBOS AÚN ESTAN EN FASE I CON TODO LO QUE ESTO IMPLICA EN CUESTIÓN DE PLAZOS ... YA QUE PARA REALUZAR 3 FASES CLÍNICAS HACEN FALTA DE 12 A 15 AÑOS ... NOS IRÍAMOS AL 2040.